Peter Caravan
Overview
Explore the profile of Peter Caravan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
202
Citations
5293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allison M, Catana C, Zhou I, Caravan P, Montesi S
J Nucl Med
. 2025 Feb;
PMID: 40015916
Fibrosing lung diseases affect over 160,000 individuals in the United States alone and can carry a prognosis that is worse than many cancers. Antifibrotic treatments modify only the rate of...
2.
Quintana J, Jiang F, Kang M, Valladolid Onecha V, Konik A, Qin L, et al.
J Nucl Med
. 2025 Jan;
66(1):91-97.
PMID: 39753366
Radionuclides used for imaging and therapy can show high molecular specificity in the body with appropriate targeting ligands. We hypothesized that local energy delivered by molecularly targeted radionuclides could chemically...
3.
Akam-Baxter E, Ridley S, Moon B, Caravan P, Sosnovik D
Circ Res
. 2024 Dec;
136(3):315-317.
PMID: 39717913
No abstract available.
4.
Esfahani S, Ma L, Krishna S, Ma H, Raheem S, Shuvaev S, et al.
Sci Transl Med
. 2024 Dec;
16(777):eadn7218.
PMID: 39661705
Patients with advanced gastric cancer (GCa) have limited treatment options, and alternative treatment approaches are necessary to improve their clinical outcomes. Because fibrin is abundant in gastric tumors but not...
5.
Izquierdo-Garcia D, Desogere P, Philip A, Sosnovik D, Catana C, Caravan P
Mol Imaging Biol
. 2024 Dec;
27(1):99-108.
PMID: 39633070
Purpose: This study presents for the first time in humans the biodistribution, clearance and dosimetry estimates of [Cu]Fibrin Binding Probe #8 ([Cu]FBP8) in healthy subjects. [Cu]FBP8-PET previously demonstrated its potential...
6.
Zhang C, Ma H, DeRoche D, Gale E, Pantazopoulos P, Rotile N, et al.
Res Sq
. 2024 Nov;
PMID: 39606447
Liver fibrosis is a common pathway shared by all forms of progressive chronic liver disease. There is an unmet clinical need for noninvasive imaging tools to diagnose and stage fibrosis,...
7.
Klinkhammer B, Ay I, Caravan P, Caroli A, Boor P
Nephron
. 2024 Nov;
149(3):149-159.
PMID: 39496240
Background: Diagnosing and monitoring kidney diseases traditionally rely on blood and urine analyses and invasive procedures such as kidney biopsies, the latter offering limited possibilities for longitudinal monitoring and a...
8.
Esfahani S, Ma H, Krishna S, Shuvaev S, Sabbagh M, Deffler C, et al.
Theranostics
. 2024 Sep;
14(15):5745-5761.
PMID: 39346545
Pancreatic ductal adenocarcinoma (PDAC) is an invasive and rapidly progressive malignancy. A major challenge in patient management is the lack of a reliable imaging tool to monitor tumor response to...
9.
Ning Y, Zhou I, Caravan P
Adv Mater
. 2024 Sep;
36(44):e2407262.
PMID: 39279542
Molecular magnetic resonance imaging (MRI) combines chemistry, chemical biology, and imaging techniques to track molecular events non-invasively. Quantitative molecular MRI aims to provide meaningful, reproducible numerical measurements of molecular processes...
10.
Moon B, Zhou I, Ning Y, Chen Y, Le Fur M, Shuvaev S, et al.
J Am Heart Assoc
. 2024 Jul;
13(14):e034363.
PMID: 38979786
Background: Aging-associated left ventricular dysfunction promotes cardiopulmonary fibrogenic remodeling, Group 2 pulmonary hypertension (PH), and right ventricular failure. At the time of diagnosis, cardiac function has declined, and cardiopulmonary fibrosis...